BLA 761228 · Immunocore LTD
Kimmtrak
Tebentafusp-Tebn · Injection · Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Jan 25, 2022: To treat unresectable or metastatic uveal melanoma
Last checked: Nov 20, 2026Latest source record: Jun 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 25, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
2 Phase 3, 12 recruiting
FAERS reports
602
457 serious, 107 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
BOXED WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated [(see Dosage and Administration (2.2) , see Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated ( 2.2 , 5.1 ).
What it is approved for
From the label in effect Aug 20, 2026.
KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).
Mechanism: Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. The TCR arm binds to a gp100 peptide presented by human leukocyte antigen-A*02:01 (HLA-A*02:01) on the cell surface of uveal melanoma tumor cells. In vitro, tebentafusp-tebn bound to HLA-A*02:01-positive uveal melanoma cells and activated polyclonal T cells to release inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumor cells.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 25, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- KIMMTRAK · TEBENTAFUSP-TEBN 100MCG/0.5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tebentafusp" as an intervention, any sponsor and status, largest first.
- Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaActive, not recruiting
University of OxfordAcademic, hospital or other
NCT05315258 · 850 participants (planned) · Start Jul 25, 2022 · Primary completion Dec 30, 2026
Drug: Tebentafusp · For: Melanoma (Skin); Melanoma, Uveal
Sites: Cambridge, United Kingdom; Glasgow, United Kingdom; Liverpool, United Kingdom · 10 sites in all
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Pivotal-lookingRecruiting
Immunocore LtdIndustry
NCT05549297 · 540 participants (planned) · Start Dec 19, 2022 · Primary completion Mar 2028
Drug: Tebentafusp; Tebentafusp with Pembrolizumab and 1 more · For: Advanced Melanoma
Sites: Phoenix, Arizona; Jacksonville, Florida; Orlando, Florida · 82 sites in all
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruiting
Immunocore LtdIndustry
NCT04262466 · 410 participants · Start Feb 25, 2020 · Primary completion Oct 2026
Drug: Brenetafusp; Brenetafusp and pembrolizumab and 5 more · For: Select Advanced Solid Tumors
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 76 sites in all
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaPivotal-lookingCompleted
Immunocore LtdIndustry
NCT03070392 · 378 participants · Start Oct 16, 2017 · Primary completion Oct 13, 2020
Drug: IMCgp100; Dacarbazine and 2 more · For: Uveal Melanoma
Sites: Los Angeles, California; Palo Alto, California; San Francisco, California · 57 sites in all
- DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid TumorsRecruiting
DynamiCure BiotechnologyIndustry
NCT05785754 · 320 participants (planned) · Start Jun 28, 2023 · Primary completion Dec 2026
Drug: DCSZ11; Pembrolizumab and 2 more · For: Advanced or Metastatic Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 35 sites in all
- Adjuvant Tebentafusp in High Risk Ocular MelanomaPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT06246149 · 290 participants (planned) · Start Nov 11, 2024 · Primary completion Nov 2032
Drug: Tebentafusp · For: Uveal Melanoma
Sites: Lake Success, New York; Brussels, Belgium; Nice, France · 15 sites in all
Immunocore LtdIndustry
NCT02570308 · 146 participants · Start Feb 29, 2016 · Primary completion Mar 20, 2020
Drug: IMCgp100 · For: Uveal Melanoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 26 sites in all
- Tebentafusp-tebn With LDT in Metastatic UMPivotal-lookingRecruiting
Thomas Jefferson UniversityAcademic, hospital or other
NCT06626516 · 109 participants (planned) · Start Oct 15, 2025 · Primary completion Oct 2030
Drug: Tebentafusp-Tebn; GM-CSF (Sargramostim) and 1 more · For: Metastatic Uveal Melanoma
Sites: Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome118
- pyrexia107
- disease progression73
- hypotension70
- rash69
- malignant neoplasm progression61
- chills59
- product dose omission issue56
- pruritus44
- nausea40
- vomiting36
- death32
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2022 | 100 |
| 2023 | 104 |
| 2024 | 134 |
| 2025 | 139 |
| 2026 | 123 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Kimmtrak (Tebentafusp-Tebn) · HCPCS J9274
2024 spending
$87.1M
Beneficiaries
174
4,017 claims
Per beneficiary
$500,504
2024 ASP limit $211.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $10,129,431 |
| 2023 | $63,236,203 |
| 2024 | $87,087,754 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P, Hassel JC, Rutkowski P, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR, McAlpine C, Woodcock VK, et al. · Clin Cancer Res 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM, Watkins C, Costa-García M, et al. · Ann Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Sacco JJ, Carvajal RD, Butler MO, et al. · J Immunother Cancer 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Five-year survival with tebentafusp in metastatic uveal melanoma.
Piperno-Neumann S, Rutkowski P, Hassel JC, et al. · Ann Oncol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Immunocore LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.